Turning Poo Into Insights.

Problem

A healthy bowel takes it all. Otherwise, something is wrong.
A bad quality of digestion is a sign for:

• Malabsorption and / or Maldigestion due to:

  • Inflammation  or Irritation of the bowel 

  • Celiac disease / Pancreatic insufficiency / Lack of bile acids

• Change in Nutrition (e.g. High Protein Diet)

• Unsuitable Enteral Nutrition (e.g. after an accident)

also neurological or neurodegenerative diseases such as Alzheimer´s Disease, Multiples Sclerosis, or Depression are associated with the bowel.

Clinical Outcomes

• Digital biomarker and longitudinal patterns in the same patients 
• Qualification & Quantification of scientific parameter and patterns
• Objective data about the digestion for the user, patient or healthcare professional
• Enabling personalized therapy
• Nutrition optimization or diet adjustment
  

  ---

• Increase Quality of Life (QoL), the energy level and productivity for patients
• Prediction and Prevention of painful phases of patients
• Reduction of Healthcare burdens & hospitalization costs
• Reduction of steroids like cortisone.

Potential User

Clinical
– Irritable Bowel Syndrome (75 million people in Europe)
– Enteral Nutrition / Malnutrition (33 million people in Europe)
– Inflammatory Bowel Disease (2.5–3 million people in Europe)
– Stoma (700.000 people in Europe)

Consumer 
– Losing / Gaining Weight (50% of adults have tried a diet to lose weight. 2% of adults want to gain weight.)
– Vegetarian/Vegans who to track their metabolizing of food 
– Parents who want to track children’s digestion

Animal 
– Cats & Dogs
– Racing Horses & Falcons

Call for Clinical Cooperations

We are calling for study- and research projects. Our Poodl-System is ready to start! Do you have a research interest in the field of gastrointestinal diseases like Colitis Ulcerosa, Crohn’s Disease, any other kind of bowel disease, or enteral nutrition? We offer new technology to analyze stool samples regularly.

We are super excited to explore what benefits the serial measurement of objective parameters or patterns in stool as an indicator for the state of health for patients, relatives, and physicians delivers.

Let’s talk about a research project and reach out to us via hello@poodl.io

Healthcare Burden

• More than 1.4 million people in Germany, primarily women, are diagnosed with Irritable Bowel Syndrom or Inflammatory Bowel Disease.
• 7-16% of the total population struggles with symptoms of an Irritable Bowel Syndrom, a similar prevalence for Europe and the United States.
• Treating IBS in Germany alone is estimated to cost over €3.2 billion per year.
• Overall annual healthcare expenditures in U.S. for gastrointestinal disease total $136 billion.
• Abdominal pain is the symptom most responsible for 22 million office visits and 6 million emergency department (ED) visits in the U.S.

Investment Opportunity

We are also raising an investment round. If the clinical validation is positive, we will face a substantial commercial opportunity. Please get in touch.

The Federal Ministry for Economic Affairs and Energy (BAFA) selected Poodl as an innovative company and is giving investors a 20% cash-refund for every investment done. Please read more here.

Crew

Lutz Haase, MBA
Founder & CEO

10+ years of digital health consulting for e.g. Bayer, Biotronik or Roche Diagnostics. Angel Investor.

Dr. Jan Kunde
Founder & CSO

15+ years of medical affairs within Bayer, Thermo Fisher Scientific, Takeda or Epigenomics.

Dr. Hardy Kietzmann
(Advisor)

20+ years in Healthcare & Pharma in the fields of innovation, business development and strategy.

Prof. Dr. Andreas Schwiertz (Advisor)

Head of R&D at MVZ Institute of Microecology & Microbiome Expert

Partner

Institute of Microecology
The specialist for microbiota and mucosal surface.

Partner

Center for biomedical image and information processing
HTW Berlin